Cargando…

Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia

OBJECTIVE: Postmenopausal women show a more atherogenic lipid profile and elevated cardiovascular risk compared to premenopausal women. The aim of this study was to investigate the efficacy and safety of high-dose atorvastatin on the improvement of the blood lipid profile of postmenopausal women in...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Jaecheol, Yoo, Soyeon, Koh, Gwanpyo, Min, Kyung-Wan, Shin, Hyun Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Lipidology and Atherosclerosis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379073/
https://www.ncbi.nlm.nih.gov/pubmed/32821729
http://dx.doi.org/10.12997/jla.2020.9.1.162
_version_ 1783562561563656192
author Moon, Jaecheol
Yoo, Soyeon
Koh, Gwanpyo
Min, Kyung-Wan
Shin, Hyun Ho
author_facet Moon, Jaecheol
Yoo, Soyeon
Koh, Gwanpyo
Min, Kyung-Wan
Shin, Hyun Ho
author_sort Moon, Jaecheol
collection PubMed
description OBJECTIVE: Postmenopausal women show a more atherogenic lipid profile and elevated cardiovascular risk compared to premenopausal women. The aim of this study was to investigate the efficacy and safety of high-dose atorvastatin on the improvement of the blood lipid profile of postmenopausal women in Korea. METHODS: This study is a prospective, open-label, single-arm clinical trial that was conducted in 3 teaching hospitals. Postmenopausal women with a moderate-to-high cardiovascular risk, according to guidelines from the Korean Society of Lipid & Atherosclerosis, were enrolled. Participants were administered 20 mg of atorvastatin daily for the first 8 weeks, and if the targeted low-density lipoprotein cholesterol (LDL-C) level was not achieved, the dose was increased to 40 mg for the second 8 weeks. The primary endpoint was percentage change of LDL-C from baseline after 16 weeks of drug administration. RESULTS: Forty-four women were enrolled, 28 of whom (75.6%) had diabetes mellitus. By the end of treatment period (16 weeks) all patients had achieved LDL-C target levels, with 33 (94.2%) of the participants achieving it after only 8 weeks of administration. After 16 weeks, LDL-C decreased by 45.8±16.7% (p<0.001) from the baseline, and total cholesterol (33.2±10.9%; p<0.001), triglyceride (24.2±37.5%; p=0.001), and apolipoprotein B (34.9±15.6%; p<0.001) also significantly decreased. Blood glucose and liver enzyme levels slightly increased, but none of the participants developed serious adverse events that would cause them to prematurely withdraw from the clinical trial. CONCLUSION: 20 and 40 mg atorvastatin was effective and safe for treating dyslipidemia in postmenopausal Korean women with moderate-to-high cardiovascular risk.
format Online
Article
Text
id pubmed-7379073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Society of Lipidology and Atherosclerosis
record_format MEDLINE/PubMed
spelling pubmed-73790732020-08-18 Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia Moon, Jaecheol Yoo, Soyeon Koh, Gwanpyo Min, Kyung-Wan Shin, Hyun Ho J Lipid Atheroscler Original Article OBJECTIVE: Postmenopausal women show a more atherogenic lipid profile and elevated cardiovascular risk compared to premenopausal women. The aim of this study was to investigate the efficacy and safety of high-dose atorvastatin on the improvement of the blood lipid profile of postmenopausal women in Korea. METHODS: This study is a prospective, open-label, single-arm clinical trial that was conducted in 3 teaching hospitals. Postmenopausal women with a moderate-to-high cardiovascular risk, according to guidelines from the Korean Society of Lipid & Atherosclerosis, were enrolled. Participants were administered 20 mg of atorvastatin daily for the first 8 weeks, and if the targeted low-density lipoprotein cholesterol (LDL-C) level was not achieved, the dose was increased to 40 mg for the second 8 weeks. The primary endpoint was percentage change of LDL-C from baseline after 16 weeks of drug administration. RESULTS: Forty-four women were enrolled, 28 of whom (75.6%) had diabetes mellitus. By the end of treatment period (16 weeks) all patients had achieved LDL-C target levels, with 33 (94.2%) of the participants achieving it after only 8 weeks of administration. After 16 weeks, LDL-C decreased by 45.8±16.7% (p<0.001) from the baseline, and total cholesterol (33.2±10.9%; p<0.001), triglyceride (24.2±37.5%; p=0.001), and apolipoprotein B (34.9±15.6%; p<0.001) also significantly decreased. Blood glucose and liver enzyme levels slightly increased, but none of the participants developed serious adverse events that would cause them to prematurely withdraw from the clinical trial. CONCLUSION: 20 and 40 mg atorvastatin was effective and safe for treating dyslipidemia in postmenopausal Korean women with moderate-to-high cardiovascular risk. Korean Society of Lipidology and Atherosclerosis 2020-01 2019-11-05 /pmc/articles/PMC7379073/ /pubmed/32821729 http://dx.doi.org/10.12997/jla.2020.9.1.162 Text en Copyright © 2020 The Korean Society of Lipid and Atherosclerosis. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Moon, Jaecheol
Yoo, Soyeon
Koh, Gwanpyo
Min, Kyung-Wan
Shin, Hyun Ho
Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
title Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
title_full Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
title_fullStr Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
title_full_unstemmed Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
title_short Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
title_sort efficacy and safety of high-dose atorvastatin in moderate-to-high cardiovascular risk postmenopausal korean women with dyslipidemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379073/
https://www.ncbi.nlm.nih.gov/pubmed/32821729
http://dx.doi.org/10.12997/jla.2020.9.1.162
work_keys_str_mv AT moonjaecheol efficacyandsafetyofhighdoseatorvastatininmoderatetohighcardiovascularriskpostmenopausalkoreanwomenwithdyslipidemia
AT yoosoyeon efficacyandsafetyofhighdoseatorvastatininmoderatetohighcardiovascularriskpostmenopausalkoreanwomenwithdyslipidemia
AT kohgwanpyo efficacyandsafetyofhighdoseatorvastatininmoderatetohighcardiovascularriskpostmenopausalkoreanwomenwithdyslipidemia
AT minkyungwan efficacyandsafetyofhighdoseatorvastatininmoderatetohighcardiovascularriskpostmenopausalkoreanwomenwithdyslipidemia
AT shinhyunho efficacyandsafetyofhighdoseatorvastatininmoderatetohighcardiovascularriskpostmenopausalkoreanwomenwithdyslipidemia